Vera Therapeutics VERA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -71.3%-31.8pp | -50.7%-5.9pp | -73.2%-8.1pp | -54.8%-8.8pp | -39.5%-2.6pp | |
| Return on assets | -59.9%-25.8pp | -43.1%-6.5pp | -56.9%-7.5pp | -44.7%-8.3pp | -34.1%-4.1pp | |
| Return on invested capital | -77.1%-32.8pp | -72.8%-21.3pp | -73.5%-7.9pp | -55.4%-7.8pp | -44.3%+8.1pp | |
| Liquidity | ||||||
| Current ratio | 13.6×-14.0× | 13.6×-12.0× | 12.2×-1.6× | 17×-4.4× | 27.7×-0.9× | |
| Quick ratio | 13.6×-14.0× | 13.6×-12.0× | 12.2×-1.6× | 17×-4.4× | 27.7×-0.9× | |
| Cash ratio | 2.5×0.0× | 6.6×+3.0× | 1.4×+0.3× | 1.5×+0.1× | 2.5×-2.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -50.7×-25.0× | -41.9×-20.0× | -36×-14.7× | -31.6×-11.4× | -25.7×-4.6× | |
| Per Share | ||||||
| Book value per share | $6.99-16.8% | $9.41-9.8% | $6.25+18.7% | $7.34+22.5% | $8.40+21.1% | |
| Valuation | ||||||
| Market capitalization | $2.87B+87.5% | $3.59B+34.2% | $1.85B-23.3% | $1.44B-21.9% | $1.53B-20.1% | |
| Enterprise value | $2.83B+85.0% | $3.32B+25.7% | $1.87B-23.4% | $1.47B-21.6% | $1.53B-19.5% | |
| Price / book | 5.7×+2.9× | 5.9×+1.3× | 4.6×-3.7× | 3.1×-2.5× | 2.9×-2.6× | |
| Free cash flow yield | -10.2%0.0pp | -6.7%-1.7pp | -11.4%-6.4pp | -13%-7.2pp | -10.2%-5.0pp | |
| Earnings yield | -12.9%-1.4pp | -8.3%-2.7pp | -13.6%-8.0pp | -15.2%-9.3pp | -11.5%-6.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vera Therapeutics's ratios come from?
- Every ratio is computed from Vera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.